PT  - JOURNAL ARTICLE
AU  - Mohamed Altai
AU  - Rosemery Membreno
AU  - Brendon Cook
AU  - Vladimir Tolmachev
AU  - Brian M. Zeglis
TI  - Pretargeted Imaging and Therapy
AID  - 10.2967/jnumed.117.189944
DP  - 2017 Oct 01
TA  - Journal of Nuclear Medicine
PG  - 1553--1559
VI  - 58
IP  - 10
4099  - http://jnm.snmjournals.org/content/58/10/1553.short
4100  - http://jnm.snmjournals.org/content/58/10/1553.full
SO  - J Nucl Med2017 Oct 01; 58
AB  - In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their pharmacokinetic limitations. The core premise of pretargeting lies in administering the targeting vector and radioisotope separately and having the 2 components combine within the body. In this manner, pretargeting strategies decrease the circulation time of the radioactivity, reduce the uptake of the radionuclide in healthy nontarget tissues, and facilitate the use of short-lived radionuclides that would otherwise be incompatible with antibody-based vectors. In this short review, we seek to provide a brief yet informative survey of the 4 preeminent mechanistic approaches to pretargeting, strategies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, and bioorthogonal click chemistry.